Boehringer Ingelheim Vetmedica Gmbh

Nobl Laboratories, Inc.

Boehringer Ingelheim Animal Health USA Inc.

Jeffrey P Knittel

Michael B Roof

Michael Beck

Jeremy Kroll

Axel Lischewski

Veljko Nikolin

Katharina Hedwig Toepfer

Konrad Stadler

Alexander Brix

Phillip Wayne Hayes

Brice Dean Lilly

Jeremy J Kroll

The present invention relates to the field of vaccines and medicaments for the prophylaxis and treatment of infectious diseases in ruminants. In particular, it relates to inactivated Schmallenberg virus (SBV) useful as vaccine or medicament for preventing or treating viremia, the transmission and clinical symptoms, in particular malformations in newborn ruminants such as cattle, sheep and goats, induced by SBV.

Schmallenberg virus (SBV) vaccine, methods of production, and uses thereof

The present invention relates to immunological compositions of outer membrane proteins (OMPs) of, as well as methods of extraction, a respiratory challenge model, methods of administration and diagnostic assays and kits.

[object Object]

The present invention relates to new attenuatedbacteria strains passaged at least 110 times. Moreover, the present invention also provides immunogenic compositions comprising live bacteria of any of those attenuatedbacteria strain, their manufacture and use for the treatment and prophylaxis ofinfections and combinations with other veterinary vaccines or medicaments.

The present invention relates to combination vaccines and/or the combined use of immunogenic compositions for the treatment and/or prophylaxis of cattle against microbiological infections, wherein the infections are caused byand at least one further cattle relevant pathogen. The combination vaccine as described herein comprises at least oneantigen, preferably the attenuated, avirulentas provided herewith and one or more further immunologically active components effective for the treatment and/or prophylaxis of infections caused by a further pathogen of cattle.

The present invention relates to new attenuatedbacteria strains. Moreover, the present invention also provides immunogenic compositions comprising live bacteria of an of those attenuatedbacteria strain, their manufacture and use for the treatment and prophylaxis ofinfections.

The present invention relates tovaccines and methods for protecting against and diagnosinginfection. The products and processes of the invention are attainable, in part, as the result of an improved method for cultivating large scale supplies of, including both a novel isolate ofof European origin and a method of preparing a lyophilized product containing the attenuated European isolate as vaccine product.

A method for large scale cultivation and attenuation of L. intracellularis bacteria by inoculating cells with L. intracellularis bacteria to infect the cells, incubating the infected cells in a reduced oxygen concentration and maintaining the infected cells in suspension. Anti-L. intracellularis vaccines are prepared from cultures grown in suspension. Diagnostic agents are also disclosed.

Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis

A method for large scale cultivation and attenuation of IS intracellularis bacteria by inoculating cells with IS intracellularis bacteria to infect the cells, incubating the infected cells in a reduced oxygen concentration and maintaining the infected cells in suspension. Anti-IS intracellularis vaccines are prepared from attenuated strains. Diagnostic agents are also disclosed.

Growing community of inventors

Parkville, MO, United States of America

Jeffrey P Knittel